Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) , a China-based pharmaceutical company, announced on August 21,...
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) , a China-based pharmaceutical company, announced on August 21,...
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...
Chinese ophthalmology specialist Ocumen Therapeutics (HKG: 1477) has announced the enrollment of more than 140...
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
Ocumension Therapeutics (HKG: 1477) announced on September 23, 2024, that the National Medical Products Administration...
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine...
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...
Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I...
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced the completion of enrollment for a...
China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...
China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...